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ABSTRACT
HYBRIDOMAS DERIVED FROM MURINE GUT ASSOCIATED LYMPHOID TISSUE
Robert Staszewski
1984
The clinical potential of specific passive mucosal
immunity is discussed and it is proposed that bulk
quantities of hybridoma produced specific dimeric
IgAs could be clinically useful as made to order super
colostrums .
slgAs function on mucosal surfaces to prevent
the adherence of pathogens. They are poor opsonins
and do not activate complement except by the alternate
pathway.
In principle mesenteric lymph node (MLN) or Peyer's
patch (PP) lymphocytes aseptically harvested from
enterically immunized and boostered mice displaying
blastogenic anamnestic response might be fused with
log phase cells of a non secreting murine myeloma
to generate specific dimeric IgA(+J) secreting hybridomas.
Lipoteichoic acid (LTA) has been demonstrated
to be the adhesin of the group A streptococci and
possibly many other gram positive mucosal pathogens.
The polyglycerolphosphate backbone common to all LTAs
is a 25-30 residue polymer affording many identical
binding sites to a single specificity (monoclonal)
antibody. Preincubation of streptococci with backbone
specific antibody has been shown to block adherence
to human buccal epithelial cells in vitro.
Murine hybridoma derived dimeric IgA anti LTA
backbone will likely have considerable ability to
block adherence of streptococcal pathogens in vitro.
In vivo it may be useful as a safe clinical agent
providing passive mucosal immunity against a wide
variety of gram positive pathogens, and might indeed
be employed as a super colostrum.
A step toward this goal was taken by demonstrating
IgA secreting murine hybridomas can be produced using
gut associated lymphoid tissue (GALT) from enterically
immunized and boostered animals.
MLN and PP lymphocytes from two groups of 5 mice
intragastrically immunized and boostered with Freund's
complete adjuvant (FCA) were separately pooled and fused
with SP2 cells.
MLN cells were found to be poor fusion partners
with a hybridization frequency 1/10 that of PP or
spleen with SP2 cells, paralleling the 1:10 concentration
ratio of surface immunoglobulin bearing blasts in
these tissues.
The 20 day post fusion supernatants of all 12 MLN
hybrids and 25 of the 35 (71%) of PP origin failed to
demonstrate antibody production on ELISA. The difference
2
is significant at P=0.1, X (ldf)=2.8, and it is conjectured
these MLN blasts were at a stage of differentiation less
adept than PP blasts at promoting antibody secretion in
SP2 hybrids.
The observation of 4 IgA, 2 IgG, and 4 IgM containing
supernatants is consistant with the 54:16:30 proportion
2
of PP blasts displaying these surface antibodies, X =.185.
No attempt was made to determine antibody specificities
as FCA was assumed to produce generalized GALT stimulation.
Work is currently in progress to assay the IgA
containing supernatants for polymeric antibody.
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INTRODUCTION
THE CLINICAL POTENTIAL OF PASSIVE MUCOSAL IMMUNITY
The neonatal immune system is naive. The ignorance
of the systemic and mucosal systems is due to their
inexperience with environmental antigens.
Maternally derived passive immunity is provided
through transplacental transfer of IgG and the ingestion
of secretory IgA (slgA) in colostrum. This slgA is
uniquely suited to passively protect the infant gut
from enteric pathogens that the mother was recently
exposed to and represent immediate threats till the
infant gut associated lymphoid tissue (GALT) can
produce enough slgA to defend itself (1,2,3).
In principle passive immunity against mucosal
surface pathogens can be provided by the application
of specific slgA to the surface as in the treatment
of selective IgA deficiency with colostrum (4,5,6).
Colostrum is difficult to obtain and the slgA of
uncertain antigenic specificity profile.
If it were available specific dimeric IgA even of
heterologous origin might safely be used to develop
agents to:
1) Treat slgA deficiency states by ingestion
or inhalation (4,5).
2) Use against the development of allergies
in children of atopic parents by blocking absorption
of potential allergens (7).
23) Provide specific short term prophylaxis or
treatment for:
a) epidemic enteric illness by neutralizing
virus or preventing the adherence of bacterial pathogens
to mucosal surfaces, e.g. rotavirus and cholera in the
gut, Neisseria meningitidis colonization of the oropharynx,
Streptococcus mutans adherence to teeth, or group A
streptococci adherence to pharyngeal mucosa (8,9,10,11,12).
b) pathogens on extraenteric mucosal surfaces,
e.g. organisms causing otitis media, Neisseria gonorrhea
or chlamydia adhering to urethral, vaginal, or conjunctival
surfaces (11,13).
4) Provide the basis for a new class of contraceptives
which might work by:
a) preventing the adherence of sperm to ovum (14).
b) preventing the adherence of the zygote to
uterine mucosa (14,15).
3MONOCLONAL ANTIBODIES IN ANY AMOUNT
In recent years bulk production of monoclonal
antibodies, antibodies of a single predetermined
specificity, has become possible by immortalizing
lymphocyte lines via SV40 and Epstein Barr virus
transformation or creating somatic hybrids of B cells
and myeloma of mice or rats (16,17,18,19). It is
even possible to produce human/mouse somatic hybrids
which secrete human immunoglobulin (20).
Hybrids are produced when short lived B cells
derived from lymph node or spleen of an animal displaying
anamnestic response to rechallange with antigen are
fused with polyethylene glycol or Sendai virus with
cells of a non secreting myeloma (19). Non immunoglobulin
producing murine myelomas currently in use (X63-Ag-8 . 653 ,
Sp2/0-Ag-14, and F0) are all descended from the IgG., k
secreting mineral oil plasmacytoma 21, MOPC 21 (22,23).
Unfused B cells die within days without proliferating
but hybrid and myeloma clones have unlimited ability
to proliferate. Selecting the few hybrids from the
very large number of myeloma clones would be difficult
if not impossible so the pioneers of the technique
devised systems ensuring the selective survival of
the somatic hybrids.
The novel technique of Wright allows for isolating
heterokaryons between any two types of cells by treating
4each with a lethal dose of an irreversible biochemical
inhibitor of complementary specificity ( iodoacetamide
or diethylpyrocarbonate) (18). Only heterokaryon
fusomas recieve full sets of unpoisoned molecules,
half from each parent.
The technique of Kohler and Milstein is based on
the use of a selective culture medium and is the current
standard (19). Hypoxanthine guanine phosphoribosyl
transferase (HGPRT) is the critical enzyme in the
mammalian purine salvage pathway, myeloma cells lacking
the enzyme must synthesize all purines de novo.
HGPRT myeloma cells are cultured in media containing
the antimetabolite 8 azaguanine before fusion to
prevent contamination with HGPRT revertant clones.
Azaguanine is toxic to normal cells because it is
salvagable as a purine analog and incorporated into
DNA, rendering it untranscribable.
Aminopterin is a folate antagonist which blocks
both de novo purine synthesis and the methylation
of deoxyuridylate to thymidylate. HGPRT- myeloma
cells cannot grow in the presence of aminopterin
even if thymidine and a salvagable purine like hypoxanthine
are supplied (HAT medium) since salvage is impossible
without HGPRT and synthesis is blocked by aminopterin.
Hybrids of B cells and HGPRT- myeloma cells
are at least temporarily HGPRT , can salvage hypoxanthine
and proliferate in HAT. Surviving hybrids may be
5subcloned and tested for production of specific antibody
by various means including radioimmunoassay (RIA),
or enzyme linked immunosorbent assay (ELISA) (24).
Promising clones can be grown in bulk culture or
stored frozen. Antibody can be recovered from culture
supernatant in a chemostat and purified via ammonium
sulfate precipitation or cells may be injected intra-
peritoneally into MHC compatible mice and antibody
rich ascites (containing 10-100 times the concentration
in supernatants) harvested (19,20,25).
Up to now the technology has focused on the
production of monoclonal IgG and IgM against viral,
bacterial, murine or human cell surface antigens
for use as laboratory investigational agents and
very recently for the experimental diagnosis and
treatment of several human malignacies (26,27).
In principle B cells obtained from tonsils,
spleen, mesenteric lymph nodes (MLN), intestinal
lamina propria, or Peyer's patches (PP) of an enterically
immunized mouse could be fused with cells of a non
secreting murine myeloma to investigate B cell differentiation
in the GALT or to produce bulk quantities of specific
dimeric IgA for clinical use.
6THE MUCOSAL IMMUNE SYSTEM
We are under siege without and within. Bacteria,
virus, protozoa, fungi, parasites, non replicating
agents, and neoplasms would overrun us but for humoral
immunity (B cell), cell mediated immunity (T cell),
phagocytosis and complement. Our defenders may turn
on us if they mispercieve self as foreign.
Secretions bathing mucosal linings and mechanical
factors (skin and ciliary clearance) are among the
first lines of defense against the external environment.
The observations that antibody levels in mucosal
fluids correlated more directly with resistance to
certain infections than did serum titers, the preponderance
of IgA in these fluids (IgA/IgG greater than 1),
that IgA, IgM, and IgE are present in larger amounts
than can be explained by simple transudation from
serum (where IgG/IgA greater than 4), and that the
antibody response in secretions was independent of
the serum response led to the concept of a secretory
immune system (28,29,30,31).
It is now known that the immunoglobulins in
external secretions are produced by plasma cells
locally in the lamina propria of the mucous membranes
of the gut, nasal mucosa, salivary, lacrimal, bronchial,
and mammary glands (32,33). In the presence of active
inflamation they are supplemented with serum proteins
7and IgG due to increased capillary permeability.
IMMUNOGLOBULIN STRUCTURE
The basic immunoglobulin monomer is a B lymphocyte
or plasma cell product composed of four polypeptide
chains. One pair of identical heavy chains (H chains)
approximately twice the molecular weight of the light
chains (L chains) (34).
There are five serologically determined classes
of H chain, A, G, M, E, D, but there are only two
such L chain classes, Kappa and Lambda (34,35).
Immunoglobulin classes are designated by there respective
heavy chain markers as IgA, IgG, IgM, IgE, and IgD.
The chains are folded into variable and constant
domains by tertiary forces and disulfide bonds, and
are held together by noncovalent forces and interchain
disulfide bridges to form a bilaterally symmetric
structure resembling a lobster.
H chain domains are labeled V , C - CT7 , thoseH H1 H4
on the L chains V and C . The antigen binding site,
specificity, and serologic idiotype is formed in the
V regions of the H and L chains. The area between
C and C (the hinge region) is relatively flexible,
Hl H2
allowing the lobster to reach out its claws for antigen.
8IgA STRUCTURE
Human serum IgA exists mainly as a 7S monomer
with 10-15% in polymeric form, and can be subdivided
into two subclasses by serological H chain markers (30,36,
37,38). IgA comprises 90% of serum IgA and marrow plasma
cell product while IgA_ makes up 40-60% of the immunoglobulin
content of secretions.
IgA,, is subdivided by allotypic H chain markers
into an IgA?M without L-H disulfide bonds, prevalent
in Caucasians, and an IgA- prevalent in mongoloid and
negroid peoples.
These antigens are responsible for the anaphylactic
and urticarial transfusion reactions encountered in
IgA deficient patients (39,40).
Pathogenic Neisseria gonorrhea and meningitidis
produce an IgA protease which cleaves a single proline-
threonine bond in the hinge region of the IgA A chain
rendering the molecule unable to agglutinate bacteria (13).
SECRETORY IgA STRUCTURE
Secretory IgA (slgA) the preponderant immunoglobulin
in secretions, is a complex molecule composed of an
IgA dimer (MW 300K), a molecule of J chain (MW 15K),
and a molecule of secretory component (SC) (MW 70K) (35,41).
J chain is a plasma cell derived glycopeptide with
9heavy glutamic and aspartic acid content, disulfide
bonded to dimeric IgA at the penultimate carboxyterminal
cysteine of the A chain, and not found associated with
monomeric IgA (41,42,43). Complexing with J chain
alters the conformation of the subunits bringing them
close enough for intersubunit disulfide bond formation
and also confering the ability to bind SC (41).
SC, an epithelial cell derived glycoprotein, acts
as a receptor for dimeric IgA+J or pentameric IgM+J on
the epithelial cell surface facing lamina propria (44).
SC initiates the pinocytosis of the dimeric IgA+J that
has diffused through the interstitium of the lamina
propria to the epithelial intercellular space and
ensures its transport onto the mucosa.
SC coils about the Fc portion of the dimer hinge
region to hinge region, stabilizing it and increasing
its resistance to proteolysis (41,44). SC has an
affinity for mucin thereby giving slgA a selective
advantage to clear slgA-antigen complexes by way of the
constantly excreted mucin.
SC is present free in normal mucosal fluids as
well as in the secretions of neonates (who normally
have no detectable IgA) and in patients with selective
IgA deficiency or agammaglobulinemia.
Polymeric IgA and polymeric IgA-antigen complexes
are rapidly cleared from plasma by transhepatic transport
into bile in mice and rats (45,46,47,48,49). It has
10
been demonstrated that dimeric IgA(+J) binds specifically
to SC on human hepatocyte membranes in vivo, but that
only 1% of an injected dose of polymeric antibody is
recovered in bile in 8 hours (45,50). Transhepatic
clearance of polymeric IgA and polymeric IgA antigen
complexes is of minor importance in humans (50).
Several reports in the literature indicate human
SC can also bind heterologous polymeric immunoglobulins
including murine polymeric IgAs (51,52).
B CELL DIFFERENTIATION
Stem cells appear in the fetal liver and travel to
the marrow (34,35). In that microenvironment some
mature to become short lived B cells, lymphocytes
characterized by immunoglobulin on their surfaces. Stem
cell maturation and antibody production are active throughout
life (34,35) .
Antibody on B cell membranes is synthesized by that
cell, IgM and IgD initially appearing simultaneously.
These thousands of surface IgM and IgD molecules act as
receptors for a single preordaned antigenic determinant.
B cells rapidly populate the spleen and central nodes (B
cells synthesizing J chain congregate in the lamina propria
and draining nodes of secretory epithelia), where encounter
with antigen will cause some to differentiate into IgM
secreting plasma cells, a primary immune response.
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Some will accept a T cell or macrophage signal
and change the class, but not the specificity of its
surface receptors, to IgG to become B^ cells. Some
B cells encounter their antigen, proliferate and
differentiate into IgG plasma cells, a secondary
immune response. Some will accept a T cell signal
and further differentiate into B. cells with surface
A
IgA, again to proliferate and differentiate to IgA
plasma cells in response to antigen.
IgE producing cells seem to arise directly from
B,, cells via T cell influence.M
SlgA SECRETING TISSUES
Fluorescent antibody techniques show the bulk
of slgA production occurs in secretory tissues (38).
IgA producing submucosal plasma cells in the human
GI tract outnumber IgG producers 20-30:1 vs peripheral
lymph nodes and spleen where the ratio is 1:5 (38).
IgM and IgE in secretions are also local products but
there are far fewer plasma cells of these classes. IgG
in most external secretions is largely a non specific
serum transudate. The lamina propria of the respiratory
and GI mucosa contain 5% IgE plasma cells vs less than
1% for spleen and peripheral nodes (33).
Human GI. tract contains IgM: IgG plasma cell
ratio of 5:1. Patients with IgA deficit often have an
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increased relative number of IgM plasma cells. Like
IgA, IgM polymers can bind SC and be transported
across epithelia. The bulk of secretory IgM contains
noncovalently bound SC (44).
SOURCE OF SERUM IgA
Serum IgA is present at about 200 mg% with a
half life of 6 days vs IgG at 1200 mg% with a half
life of 22 days, despite synthesis rates of 36 mg/kg-day
and 24 mg/kg-day respectively (30,37).
In humans the origin and role of serum IgA is
obscure. It is possible that monomeric and polymeric
IgA are synthesized at secretory sites and that the
smaller 7S monomer diffuses into serum by way of
lymphatics while the 10S dimer is moved onto the
epithelial surface by the preferential binding of SC
for dimer IgA and intraepithelial transport (44).
Alternatively fluorescent antibody studies show greater
than 40% of the immunoglobulin containing cells in
bone marrow were IgA class (as yet the extent of
marrow IgA synthesis is unmeasured) (38).
GALT
The gut associated lymphoid tissue consists
of the MLN, PP, and the innumerable lymphoid follicles
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in the lamina propria of the small gut (32). Gut
lymphatics drain the lymphoid follicles and PP to the
mesenteric nodes which eventually drain to the thoracic
duct (32,53,54,55).
Thoracic duct lymph contains two lymphocyte
populations distinguished by size, small lymphocytes,
and large lymphoblasts. Radiolabeling experiments
in mice, rats, and rabbits, show the small cells
disperse among all lymphoid tissues while the lymphoblasts
concentrate in small gut lamina propria, with a few
localizing in the spleen, and essentially none in
peripheral nodes (32,53,54,55). This suggests the
possibility that lymphoblasts originated in the GALT
and that these cells (or progeny) migrate to secretory
organs where they give rise to dimeric IgA secreting
plasma cells in the lamina propria (53,54,55).
Preferential migration of PP lymphocytes to
spleen and small gut lamina propria and of MLN lymphocytes
primarily to small gut has been demonstrated in animal
models by the injection of radiolabeled cells (32,53,54,55).
LYMPHOCYTE MEETS ANTIGEN
Antigen reaches B and T lymphocytes in PP or
bronchial associated lymphoid tissue (BALT) through
microfold (M) cells, heavily vacuolated specialized
epithelial cells lacking microvilli, overlying the PP (32,33).
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Precommitted antigen specific cells begin their migration
entering afferent lymphatics, travel to MLN or bronchial
nodes and thereby to the thoracic duct circulation
and finally seed secretory tissue lamina propria
throughout the body whether or not antigen is present
there (32,33,53,54,55) .
Local antigenic stimulation triggers an anamnestic
lymphocyte proliferation and increased slgA production.
The response is highly T cell dependent, and in certain
cases of IgA deficiency the defect may be in the
helper Ts (56). Observations that IgA production
is absent in the athymic 'nude' mouse, and that neonatal
thymectomy markedly reduces IgA secretion, imply
T cell help is crucial for production of IgA (57).
REGULATION OF IgA PRODUCTION
Suppressor Ts in the peripheral blood constitute
20% of circulating T cells, most carry surface receptor
for the Fc portion of IgG (TG cells) and most of
these regulate IgM and IgG production by secretion
of soluble immune response factors that regulate
helper Ts in a manner which may or may not be antigen
or immunoglobulin class specific (58,59,60). TG cells
may effect helper subsets needed for B cell differentiation
to IgA plasma cells. Six percent of peripheral lymphocytes
are TA but whether they function as helpers or suppressors
is unknown (58,59,60). TG and TA cells may represent
different stages of differentiation akin to B cell stages.
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LOCAL IMMUNITY
slgA titers in local secretions are better correlated
with resistance to viral infections such as polio in
the gut and rhinovirus in the nasopharynx than are
serum titers (61).
Viral replication in the mucosa of the respiratory
or GI tract may remain local with rhinovirus, RSV ,
myxovirus, and adenovirus, but with polio, echo and
measles virus subsequent systemic infection occurs
unless serum immunoglobulin is present to neutralize
the viremia ( 61 ) .
Salk vaccine, killed polio virus systemically
administered, results in effective immunity via systemic
IgG without secretory response, but permits persistant
virus carriage on the GI mucosa (61).
Sabin live oral vaccine induces both secretory
and systemic immunity and prevents the establishment
of a carrier state (61).
Dissociation of systemic and local immunity
occurs in RSV infection. Despite specific transplacentally
aquired maternal IgG, RSV is a frequent cause of
infantile bronchiolitis. Parenteral inactivated
vaccine generates high IgG iters without increased
protection, and may result in more serious disease
secondary to the transudation of complement fixing
IgG onto local sites of RSV multiplication (62).
16
s IgA ACTIONS
Low complement levels, small numbers of phagocytes
in mucosal secretions, inability of slgA to fix complement
except by the alternative pathway and its poor opsonic
ability are consistent with a strategy of avoiding
an inflamatory reaction on mucosal surfaces. If the
slgA barrier is penetrated IgG and IgM will be encountered
in the lamina propria and significant tissue damage
initiated, as in some colitis (63).
slgA, mechanical factors, and other agents in
secretions appear to act by neutralizing virus, exotoxins,
and preventing the adhesion of pathogens to mucosal
surfaces (3). Mucous blanket flow, cilial beating
in tracheal epithelium, bowel peristalsis, fluid
flow, and epithelial desquamation coupled with slgA
binding bacterial surface antigens, all act to inhibit
adherence and colonization in infections with pathogens
like, cholera, salmonella, and streptococci (3,8).
slgA from parotid secretions selectively inhibits
attatchment of certain oral streptococcal strains
to buccal epithelia (8,12). Cariogenic strains of
S . mutans produce a dextran from sucrose that somehow
allows the bacteria to adhere to the smooth surfaces
of teeth. slgA in the saliva of rats orally immunized
by feeding with S. mutans inhibits adherence by directly
blocking surface structures and by inhibiting glucosyl-
transferases, thereby dextran production (64). A great
17
deal of work has been done on the development of a carries
vaccine (64) .
Local immune reactions provide a means of limiting
gut and respiratory tract absorption of intact macro-
molecules by forming nonabsorbable macromolecular
complexes that are degraded by bronchial and gut
enzymes. Patients with slgA deficiency have high
serum IgM and IgG titers against milk and other food
antigens, presumably due to their uncontrolled absorption
(63,65). Circulating immune complexes with exogenous
antigens and the continuous absorption of macromolecules
possibly cross reactive with self antigens, may help
explain the clinical association of IgA deficiency
and some autoimmune disease (63,66,67).
Antigen specific suppressor T cells migrate
from PP to the spleens of enterically immunized animals
where they produce soluble suppressor factors (68,69,70).
Under certain conditions enteric immunization induces
specific systemic non reactivity to antigen, oral
tolerance including the abbrogation of contact sensitivity,
classically known as the Sulzberger-Chase phenomenon (68,
69,70,71) .
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IgA DEFICIENCY
DEFINITIONS
slgA concentration undergoes diurnal variation,
varying with site, flow rate, and composition of secretion.
In screening for IgA deficiency both serum and secretory
levels are assayed. For convenience most studies
have assayed salivary slgA (31).
Normal infants have 21+13 mg% serum IgA, while
adult values are 10 times that at 200+61 mg% (29).
Serum IgA levels consistantly 2 standard deviations
below these values constitute deficiency.
In all humoral deficiencies clinically described
there is detectable immunoglobulin, sometimes trace,
implying that structural gene deletion is rare (60).
Many asymptomatic adults have serum levels in
the 25-75 mg% range (possibly compensitory mechanisms
such as increased slgM levels are responsible) .
All symptoms, signs, and disease associations
of IgA deficiency are found with serum levels below
5 mg%, even though there are rare individuals with
near absent levels who are otherwise normal (29,72,73).
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SELECTIVE IgA DEFICIENCY (SIgAD)
Selective IgA deficiency refers to the state where: (74,75)
1) Serum IgA levels are persistantly below 5 mg%.
2) Levels of IgM, IgG are normal or elevated.
3) Repeated measurement of salivary slgA at the same
time of day are less than 2 mg%.
IgE levels are usually found to be normal
3% of screened populations have normal slgA
but documented serum IgA deficiency and are asymptomatic (74).
Rare patients with normal serum IgA levels but slgA
deficiency will be brought to attention by clinical
symptoms and signs (75).
Selective IgA deficiency as defined here has
been detected with a prevalence of 1/350-1/3040 depending
on the survey, with a median value of 1/500, making it
the most common permanent immunodeficiency state (76).
Five variations of selective IgA deficiency are
commonly noted: (67,77,78,79)
1) In asymptomatic persons compensating via unknown
mechanisms .
2) In asymptomatic persons compensating with slgM.
3) Patients with symptoms, signs attributed to
the deficiency.
4) 5-20% (excluding those with combined immunodeficiencies)
will have T cell function anomalies.
5) Up to 20% of those symptomatic in categories 3)
and 4) have other diseases with frequency of
20
occurance so low that chance association is
unlikely e.g. atopic disease, recurrent respiratory
disease (bronchitis, bronchiectasis, recurrent
pneumonia, pulmonary hemosiderosis, GI and nervous
system disease, malignancy, and most commonly,
autoimmune diseases, accounting for 50% of the
total .
Hypogammaglobulinemia is common in families of
SIgAD patients with both autosomal dominant and recessive
inheritance reported (73). Many cases are associated
with deletions in chromosome 18 or a ring 18, but the
finding is inconstant and allotypes of IgA segregate
independently (80,81).
Acquired IgA deficiency occurs in patients
treated with DPH or penicillamine, is frequently
associated with sinopulmonary tract infections, and
may return to normal levels when the drugs are dis
continued (77,82,83). Recent work suggests that
immune disturbances may precede the drug use (84).
Twin studies hint environmental factors during
fetal life can cause increased penetrance of the
defect in susceptibles . Celiac disease, recurrent
URI, and IgA deficiency were reported in one monozygous
twin, and selective IgA deficiency has been noted in
one of HLA identical twins with thyroiditis and
diabetes (85) .
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CLINICAL CHARACTERISTICS OF SlgA DEFICIENCY
Viral and bacterial infections of the upper and
lower respiratory tract, middle ear, and GI tract
are especially common in SIgAD children (86).
Recurrent sinopulmonary disease is the most
common presentation overall, with an occasional
patient coming to attention because of recurrent or
chronic right middle lobe pneumonia (77,86). Pulmonary
hemosiderosis is more common than expected (77,86).
The prevalence of SIgAD among atopics is 1/400-
1/200 vs 1/800-1/600 in normals (63,65,68). The
reduction in serum IgA may result in decreased competition
for antigen increasing the likelihood of combining
with IgE. The decreased slgA may result in absorption
of near intact proteins and increase the likelihood
of sensitization.
Increased prevalence of antibody to bovine
proteins, and circulating immune complexes including
bovine immunoglobulins have been noted in slgA deficiency
(65). Removal of bovine products from the diet hasn't
been clearly associated with clinical improvement.
30-40% of SIgAD patients have serum anti IgA
antibodies,most without history of blood product
administration (39,40,66). A few may develop anaphylactic
reactions following parenteral administration of blood
products. Sensitization may have occured during breast
22
feeding in infancy, transplacental maternal IgA
transfer or cross reaction with bovine immunoglobulin (63,65).
Celiac disease, ulcerative colitis and regional
enteritis are over represented among these patients (87).
Systemic lupus erythematosis, rheumatoid arthritis,
dermatomyositis, thyroiditis, pernicious anemia,
Sjogren's syndrome, and chronic active hepatitis
are all occasionally seen in association with SIgAD
but only the increased prevalence of SIgD in SLE
and RA is statistically significant. The clinical
presentations and presence of characteristic antibodies
in these diseases do not significantly differ in
those patients with IgA deficiency (67,78,79,88).
SIgAD has been reported in patients with reticulum
cell sarcoma, squamous cell carcinoma of lung and
esophagus, and thymoma, several cases with associated
autoimmune disease and recurrent infection (67).
PATHOGENESIS
In a few cases inappropriate suppressor T cell
activity results in SIgAD. B cells isolated from
Ts and exposed to polyclonal B cell activators (like
pokeweed mitogen) will secrete IgA (60).
Some investigators have found cases of intrinsic
B, cell defects, others have noted defects in TA
helper cell activity, and still others have found
combinations of these defects (56,58,59,60). Non-
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specific T cell defects are present in 10% of patients
with SIgAD (56,58,59,60). The association of auto
immune disease and SlgA deficiency may be due to a
shared disturbance in T cell function.
TREATMENT
Currently there is no effective treatment for
selective IgA deficiency other than direct antibody
replacement on mucosal surfaces in the form of colostrum (1,
2,3,4,5). Eye drops, ear drops, nose drops, or ingested
colostrum have all been used to treat particular
infectious complications of SlgA deficiency with
good success (1,2,3,4,5).
Colostrum is the high slgA content, 1000 mg%,
post partum product of the mammary glands. Ingesting
a colostrum bolus provides the neonate with specific
passive immunity of days duration to gut pathogens
in the mothers environment ( 1 ) .
It has been demonstrated that maternal enteric
immunization increases the titer of specific slgA
antibody in colostrum and milk, and enteric vaccination
of pregnant women to ensure their colostrum contains
protective slgA titers against gut organisms that
cause epidemic disease in neonates has been suggested (1).
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PRODUCING HYBRIDOMAS SECRETING DIMERIC IgA ( +J )
In a typical attempt to produce murine hybridomas
one lymphocyte per two or three hundred thousand
undergoes successful fusion. The number of antigen
specific hybridomas produced is directly correlated
with the number of B cell blasts (size determined)
at fusion (20,89) .
Using spleen as a lymphocyte source and conventional
parenteral immunization techniques, less than 1% of
hybrids produced will secrete IgA (90). These low
yields encourage the investigation of alternate techniques
of immunization and sources of lymphocytes.
ORAL (ENTERIC) IMMUNIZATION
Andre et al have found primary orogastric immunization
of BALB/c mice (the strain often used in hybridoma work)
with sheep red blood cells on four consecutive days
produces a biphasic delayed peak response of 100 IgA
indirect plaque forming cells (IPFC) and 50 IgM PFC per
million gut lymphocytes after 14 days (91).
Second immunizations for four consecutive days at
14 and 90 days induced earlier peak anamnestic responses
of 250 IgA IPFC and 150 IgM PFC per million at 23 days
and 450 IgA IPFC and 300 IgM PFC per million at 94 days (91).
In an earlier study they noted oral immunization
induced IgA IPFC and IgM PFC in the spleen, but second
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immunization did not induce a secondary response there (92).
In this experiment immunization immunization induced
greater and prolonged biphasic primary delayed peak
response in the gut, suggesting that IPFC and PFC
detected previously in the spleen were gut lymphocytes
on their way back to the gut.
Second immunization yielded increased gut response
without any splenic response, secondary to tolerance
or because the gut cells didn't recirculate. These
findings suggest the absence of splenic response occurs
because the memory cells don't recirculate but are
retained in the gut (91,92).
Plasma immunoglobulin response did not differ in
primed and boostered animals, concurring with previous
observations on the poor correlation of circulating
antibody levels and local immunity (91).
These observations imply fusions using splenic
lymphocytes containing specific IgA IPFC after primary
intragastric immunization might produce specific
dimeric IgA producing hybrids.
Since intragastric boostering produces no secondary
splenic response, fusions using spleens from boostered
mice are paradoxically less likely to produce specific
IgA secreting hybridomas than using spleens from
primarily immunized animals.
The gut limited IgA anamnestic response to intra
gastric immunization and boostering observed in these
experiments implies fusions using GALT may result in
high frequencies of specific dimeric IgA secreting hybrids.
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THE NATURE OF THE LARGE DIVIDING CELLS IN THE GALT
Guy-Grand et al studied suspensions of murine
(BALB/c) lymphocytes from peripheral lymph node (PLN),
Peyer's pathches (PP), mesenteric lymph node (MLN),
and thoracic duct lymph (TDL) (53). Cells were incubated
in vitro with tritiated thymidine (to identify blasts),
followed by immunof luorescent staining and autoradiography.
Their results may be summarized:
%blast %Bblast %blast %Bblast %blast %blast
%blast Bblast with with with with with
surface surface internal internal surface
IgA IgA IgA IgA Ig
PLN 2.6 61 3 0.5 0.4 0.06
PP 4.2 77 38 1.2 0.9 0.3 2.2
MLN 1.7 45 13.7 0.1 6.6 0.5 0.22
TDL 0.5 33 27 0.4 16 0.3
PP were found to be an especially rich source
of blasts bearing surface IgA. PP, MLN, TDL demonstrated
approximately equal % IgA containing blasts. All cells
with internal IgA (ilgA) also displayed surface IgA. PLN
was an especially poor source of ilgA blasts.
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20 hours after injection of tritiated thymidine
labeled lymphocytes from these tissues they observed
the results summarized:
% Label Density Found in Spleen
SOURCE PLN MLN PP GUT
PLN 64 25 7 1
PP 1 5 14 5
MLN 34 90 62 40
TDL 8.4 43 8 3 630
PP blasts homed mainly to spleen, while those
from MLN and TDL accumulated in the intestinal mucosa
(small bowel concentration 8 times large bowel) and PP.
The number of IgA plasma cells found in the gut lamina
propria was directly proportional to the number of
donor blasts containing ilgA. Apparently it is the
ilgA blasts which home to gut to become IgA plasma cells
Craig and Cebra's observation that transfer of PP
lymphocytes into lethally irradiated rabbits leads to
the appearance of labeled IgA plasma cells in spleen
and gut might be explained by maturation of the
dividing transfered cells to permit increased ilgA
synthesis (32,55). It is concievable that while
acquiring the capacity to synthesize ilgA B blasts
shift to producing dimeric IgA, and that dimer or
J chain on the cell membrane somehow interacts with
SC to cause the homing effect (55).
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These experiments imply PP and MLN would be
optimal lymphocyte sources for generating dimeric IgA
secreting hybridomas if enough cells could be harvested
under aseptic conditions from a properly immunized
and boostered mouse .
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AN INTERESTING ANTIGEN, LIPOTEICHOIC ACID
Teichoic acids (TA) are substituted polymers
of glycerol or ribitol phosphates in the cell walls
and membranes of gram positive bacteria (93,94).
Cell wall TAs are covalently linked to the
peptidoglycan of some bacterial cell walls under
most growth conditions. Studies in several bacteria
indicate that wall TA is located sufficiently close
to the surface for specific antibody reactions to
occur (95) .
Membrane TAs, lipoteichoic acids (LTA), are a
more characteristic component of gram positive bacteria,
and not as dependent on growth conditions as the
wall polymers (94). LTAs are polymers of 1-3 phospho-
diester linked glycerophosphate residues (typically 25-
30), the backbone, variously substituted with glycosyl
and D-alanyl esters, and covalently bound to a glycolipid
(identical to the free glycolipid of the plasmalemma,
primarily palmitic acid) through a phosphodiester
bond between a sugar hydroxyl of the glycolipid
and the terminal residue of the TA (total MW 10,000) (94).
LTAs of some organisms provolk serological
reactions. The group antigen of the group D streptococci
is an LTA (95). IgM, IgG, and IgA humoral responses
have been noted.
Wicken et al propose a wall-membrane model to
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explain these results (94,96). LTA molecules are
envisioned as imbedded in the plasma membrane by
their hydrophobic tails, while their polar glycerol -
phosphate chains are intercalated in the polysaccharide
peptidoglycan network of the cell wall. Depending
on cell wall thickness, peptidoglycan cross linking,
the number of residues in the polar chain and its
conformation in the cell wall, the distal residues
could behave as surface antigens. By labeling thin
sections of bacteria with backbone specific rabbit IgG
then with ferritin labeled goat anti rabbit IgG, they
observed label extending from the cell membrane
through the cell wall and in some cases beyond.
RANTZ ANTIGENS
LTAs will directly sensitize erythrocytes because
their lipid moiety can dissolve in the mammalian
cell membrane. Hemagglutination may be used to detect
low concentrations of LTA and or antibody to LTA (93,94,95).
Rantz antigens, erythrocyte sensitizing antigens
obtained from saline washings or culture fluid of
gram positive bacteria are presumed to be LTAs (93).
It has been noted that culture fluid from oral strepto
cocci and lactobacilli may contain up to 50 micrograms /ml
of LTA, an amount comparable to that in the cell mass.
Whether this is evidence LTA is secreted, 'or results
from turnover of cell wall or membrane is unknown (97).
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ANTI BACKBONE
In most cases when anti LTAs have been detected
in human serum they have been directed against the
polyglycerolphosphate backbone (94,95,96). The
degree of substitution determines whether the antibodies
are backbone or substituent specific (95). Antibodies
to backbone seemingly account for the observations
of a common gram positive antigen (93,95).
Group specific anti LTAs from group D and N
streptococci and group F lactobacilli are substituent
specific (95). Anti L. casei LTA (unsubstituted)
is naturally backbone specific and cross reacts
with a variety of LTAs (94,95,96). Substituted
LTAs may also generate backbone specific antibodies (95).
It is possible that one organism may act as a primary
stimulus for the production of backbone antibody
and that a variety of organisms may provide subsequent
stimuli .
CROSS REACTIVITY WITH MAMMALIAN ANTIGENS
Wicken et al speculate anti LTA in humans may
cross react with cell constituents and participate
in inflamatory sequelae to streptococcal infections
like rheumatic fever or glomerulonephritis (95,96).
Cross reaction with complement fixation by
anti backbone with cardiolipin (diphosphatidylglycerol)
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could explain biological false positive syphilis tests (99).
Beachey et al demonstrated LTA is a T cell mitogen,
and that although LPS and LTA are both amphipathic
molecules binding via lipid tails to mammalian lymphocyte
membranes, LTA selectively acts as a T cell mitogen
while LPS selectively stimulates B cells (100).
Studies in which parenteral administration of
LTA is used to induce experimental nephritis, delayed
hypersensitivity, and experimental arthritis are currently
under way ( 101 ) .
Lafer et al studied the diversity of antibodies
produced in systemic lupus erythematosis (SLE), especially
those reacting with nucleic acids, native or denatured
DNA and RNA, nucleoproteins, cell surface antigens,
cardiolipin, and anticoagulant factors (102). Antibodies
of these sorts were often reactive with the sugar
phosphate nucleic acid backbone, phosphodiester linkages
separated by three carbons of adjacent sugars (102).
These structural features are also found in cardiolipin
and the backbone of LTA, and may explain the false
biological syphilis tests seen in SLE (102,103).
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LTA AND ADHERENCE TO EPITHELIA
Bacterial adherence is prerequisite for colonization
and invasion of mucosal surfaces.
Ofek et al studied adherence of group A streptococci
to buccal epithelial cells in vitro (3,10,104).
They demonstrated both LTA and its lipid moiety
prevented the adherence of streptococci to preincubated
epithelial cells. Streptococci preincubated with anti LTA
lost the ability to adhere to epithelial cells. They
further showed that adherence inhibitory effects of
antisera directed against whole group A bacteria was
attributable to the presence of anti LTA titers. They
^conjectured the binding of LTA via its lipid tail to
mammalian cell membranes may play the central role in
the binding of gram positive pathogens to mucosal
surfaces .
Recent work by Beachey et al demonstrated that
the lipid moiety of LTA exposed in protein (largely M
protein) LTA complexes on the surface of group A stepto-
cocci is the adhesin mediating attatchment of the
organisms to the lipid binding sites of fibronectin
(the receptor) on human cell membranes (105). It
was shown that the number of streptococci capable of
adhering is directly proportional to the fibronectin
present on epithelial cells, and that preincubation of
streptococci with fibronectin inhibits adhesion.
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Ofek and Beachey studied the relation of epithelial
binding and surface fimbriae of streptococci (11).
Previous observations by Ellen and Gibbons suggested
fimbriae were intimately involved in the binding to
mucosa (3,104,106). Swanson et al had demonstrated
an association of the antiphagocytic M protein and these
fimbriae (106). It was later noted by Ellen and Gibbons
that M protein producing streptococcal strains adhere
to epithelia while M negative strains (later shown
lacking fimbriae) do not (104). Epidemiologic studies
consistently demonstrate more than half the strepto
coccal strains isolated from humans lack M antigens (107).
Ofek and Beachey found organisms treated with
pepsin at pH 5.8 retained their fimbriae and mucosal
binding ability though they lost their M protein and
resistance to phagocytosis (11).
Dissociation of resistance to phagocytosis and
epithelial binding ability has been reported in piliated
gonococci and piliated Proteus mirabilis, suggesting
the distinction between these virulence mechanisms
may be a more general phenomenon among pathogens.
Using the in vitro adherence assay they showed
streptococcal binding to treated cells was inhibited
by LTA, but not by M protein, C carbohydrate, peptido
glycan, or lipopolysaccharide (11). As before adherence
was blocked by preincubating the bacteria with anti LTA.
Further work by Alkan, Ofek, and Beachey demonstrated
LTA inhibited binding of streptococci to skin as well as
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oral epithelia (12).
Rolla et al have proposed LTA might be a crucial
element in the adherence of sucrose grown Streptococcus
mutans to dental enamel by charge interaction between
the numerous anionic backbone phosphate groups and enamel (64).
LTA trapped in the polysaccharide coat of S. mutans
accounts for the threefold increase in cell bound LTA
when 5% sucrose is substituted for 5% glucose in the
culture medium. Further, sucrose grown S. mutans has
twice the affinity of glucose grown strains for hydroxyapatite
(HA), and behaves as negatively charged molecules with
respect to HA in the presence of competing ions.
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RECENT RELATED WORK OF OTHER INVESTIGATORS
A year into the current work two reports of related
investigations appeared.
Colwell et al were able to generate high numbers
of anti trinitrophenol (TNP) polymeric IgA secreting
hybridomas by priming germ free BALB/c mice with sheep
red blood cells (SRBC) via intragastric intubation
on two consecutive days followed one week later by
intubation with TNP haptenated SRBC, after 7 days
spleen cells were fused with the non secreting murine myeloma
(X63.Ag8.653) (108). 65.4% of hybrids produced anti TNP,
54% of IgA class, with the remainder equally distributed
between IgM and IgG. They report greater than 90% secreted
IgA was polymeric.
They have also produced hybridomas secreting
IgA specific to surface determinants of an etiologic
agent of human dental carries, the gram positive S. mutans.
The success of their work is consistant with
Andre et als observations on the development of IgA
IPFC in the spleens of mice as part of the primary
response to intragastric immunization (as previously
noted) .
Dean et al were able to produce a rat hybridoma
secreting cell surface antigen specific polymeric
IgA by fusing MLN cells from rats immunized by direct
injections of allogenic cells into PP at a 14 day
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interval. Two days after the second injection MLN cells
were fused with a rat myeloma (Y3 .Ag.l .2 .3) (109).
Presumably antigen leaking into MLN afferent lymphatics
triggers an anamnestic blastogenic response there. The
polymeric nature of the IgA was demonstrated by the kinetics
of the disappearance of radiolabeled antibody from the blood
and subsequent reappearance in the bile (via transhepatic
transport) after IV injection of a rat.
A good idea often independently occurs to many people
at about the same time.
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MURINE DIMERIC IgA ANTI BACKBONE AS A POTENTIAL CLINICAL AGENT
slgAs function on mucosal surfaces to prevent
the adherence of pathogens. They are poor opsonins,
and do not activate complement except by the alternate
pathway.
Dimeric IgA (+J) will stabilize by binding to
free SC in mucosal secretions, and it has been shown
human SC has considerable affinity for heterologous
polymeric antibodies including murine polymeric IgA (+J)s.
Hybridoma technology may soon provide the ability
to produce limitless quantities of human or heterologous
specific dimeric IgA for use as specific passive mucosal
immune agents, in effect made to order super colostrums.
In principle MLN or PP lymphocytes aseptically
harvested from enterically immunized and boostered
mice, or splenic lymphocytes from recently immunized
but unboostered mice displaying anamnestic blastogenic
response might be fused with log phase cells of a
non secreting murine myeloma to generate specific
dimeric IgA secreting hybridomas.
LTA has been demonstrated to be the adhesin of
the group A streptococci and possibly many other gram
positive epithelial pathogens.
Preincubation of streptococci with backbone specific
antibody has been shown to block adherence to human
buccal epithelial cells in vitro.
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The polyglycerolphosphate backbone common to all
LTAs is a 25-30 residue polymer affording many identical
binding sites to a single specificity (monoclonal)
antibody.
Murine hybridoma derived dimeric IgA anti LTA
backbone will likely have considerable ability to
block adherence of streptococcal pathogens in vitro.
In vivo it may be useful as a safe clinical agent
providing passive mucosal immunity against a wide
variety of gram positive pathogens, and might indeed
be clinically employed as a super colostrum.
A step toward this goal is demonstrating IgA
secreting murine hybridomas can be produced using
GALT from enterically immunized and boostered mice.
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MEDIA
Media required in the fusion protocol were prepared
as follows:
100 x HT
38.8 mg Thymidine MW 242.2 (Sigma)
136.1 mg Hypoxanthine MW 136.1 (Sigma)
100.0 ml DD H20 warmed to 80-90 C
filter sterilized and stored at -20 C in 5 ml aliquots
100 x A
35.2 mg Aminopterin MW 440.4 (Sigma)
100.0 ml DD H20
filter sterilized and stored at -20 C in 0.5 ml aliquots
8-Azaquanine
200.0 mg Azaguanine MW 152.1 (Sigma)
10.0 ml DD H20
dissolved by adding IN NaOH and brought up to 20 ml
with DD H20, filter sterilized and stored at -20 C
in 1 ml aliquots
MEDIUM FOR SP2
500 ml RPMI 1640 (Gibco)
5 ml HEPES (Gibco) 1M
50 ml Calf serum heat inactivated in 56 C water bath 45 minutes
10 ml Penicillin 5000 iu/ml -Streptomycin 5000 mcg/ml (Flow)
1 ml Azaguanine
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HT MEDIUM
500 ml DMEM with 4500 mg/1 glucose (Gibco)
5 ml HEPES
5 ml Sodium pyruvate (Flow lOOmM)
5 ml HT
50 ml NCTC 109 (Microbiological Associates)
100 ml Fetal calf serum heat inactivated
5 ml Antibiotic-antimycotic (Gibco)
Penicillin 10,000 IU/ml
Streptomycin 10,000 IU/ml
Amphotericin 2 5 mcg/ml
HAT MEDIUM
HT medium
0.5 ml 100 x Aminopterin
50% POLYETHYLENE GLYCOL 1500 (BDH-Gallard Schlesinger)
20 g PEG Autoclaved 30' in a 100 ml bottle
20 ml DMEM added to cooling but still molten PEG
stored at room temperature in 1 ml aliquots
SP2 myeloma kindly provided by Dr. Kim Bottomly
All cultures were incubated in 8% C0_ at 37 c
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MATERIALS AND METHODS
Immunization Schedule
On two four consecutive day periods three weeks
apart 5 mice fasted 8 hours were placed in a saturated
diethylether atmosphere at room temperature for twenty
seconds, restrained and orogastrically intubated to
6 cm with a #20 polyethylene tube (Intramedic 0.011"
inner x 0.024" outer diameter) and 0.2 ml of Freund's
complete adjuvant delivered from a tuberculin syringe
abutted to the tubing by a #27 needle.
Source of Lymphocytes
On the final day mice fasted 8 hours were killed
by cervical dislocation. The peritoneal cavity was
immediately aseptically opened and mesenteric lymph
nodes dissected out from cecum to the root of the
mesentery as a single mass and placed in a small sterile
Petri dish containing 5 ml sterile Hanks Balanced Saline
Solution (HBSS, Difco) warmed to 37 C .
The bowel was fanned out and approximately 10
Peyer's patches removed with microdissecting scissors
from the serosal side of the ileal antimesenteric
border without entering the bowel and placed in a
separate sterile Petri dish containing 5 ml sterile
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warmed HBSS.
Pooled tissues in the MLN and PP dishes were
teased apart with sterile needles, debris allowed
to settle for one minute, and the lymphocyte rich
supernatants removed with sterile Pasteur pipettes.
Expected recoveries are 40 million and 10 million
lymphocytes respectively, roughly half that of a single
spleen.
Fusion
On the day before fusion SP2 cells were transfered
to azaguanine free medium to deplete intracellular
pools and PEG was placed in an 8% CO., incubator to
adjust pH .
SP2 cells washed in 37 C DMEM and freshly harvested
lymphocytes were mixed 3:1 in a 15 ml centrifuge tube
and spun at 1,500 rpm for 10', supernatant removed
with pellet intact. 0 . 8 ml PEG was added to the pellet
over 1', mixing gently with the pipette tip and the
tube hand warmed 1
'
. 1 ml of DMEM was added over 1
'
and the tube again hand warmed 1
' before adding 10 ml
DMEM over 2' and spinning at 1,500 rpm 10' then removing
the supernatant. The pellet was resuspended in HAT
medium to 10-100 million cells/ml and .1 ml added
to each of the inner 60 wells of 96 well microtiter
plates, the outer 36 wells
of which were prefilled
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with a saturated aqueous copper sulfate solution.
On the 4th and 7th days post fusion half the
supernatant from each inner well was aspirated with a
Pasteur pipette and replaced with .1 ml HAT medium,
then fusomas were fed HT medium at 3-5 day intervals.
Clones were macroscopically evident at 10-20 days.
ELISA for Murine Antibody Class
200 microliters of 1:20 borate buffered saline (BBS,
pH 8.4) dilution of lmg/ml rabbit anti mouse immunoglobulin
(Bionetics) was added to each well of a polyvinyl
chloride microtiter tray (Linbro) and incubated overnight
at 4 C. The tray was washed 5 times in phosphate
buffered saline (PBS, pH 7.4) then blocked by adding
200 microliters of 10% bovine serum albumin (Gibco) in
BBS, incubating 4 hours at room temperature and again
washing 5 times with PBS.
100 microliters of 1:1 BBS diluted supernatant
was added to each of the inner 60 wells, incubated
4 hours at room temperature and washed 5 times with
PBS.
100 microliters of 1:200 BBS diluted 1 mg/ml
alkaline phosphatase conjugated goat anti mouse immuno
globulin (Bionetics) was placed in all wells, incubated
4 hours at room temperature and washed 5 times with PBS.
100 microliters of a 0.1% solution of p-nitrophenyl-
phosphate disodium in diethenol amine buffer ( pH 9.8) was
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added to all wells, incubated 2 hours at room temperature,
and reaction terminated by the addition of 100 micro
liters IN NaOH to all wells. Absorbance at 405 ran was
measured with a Titertek multiscan photometer (Flow) .
Positive wells were assayed for antibody class
as above by using 1:500 BBS dilutions of 1 mg/ml alkaline
phosphatase conjugated goat anti mouse IgA, IgG, and
IgM respectively.
Protocol
Two separate groups of five female 12 week old
BALB/c mice (Jackson) were immunized and boostered
with undiluted Freund's complete adjuvant as above.
Lymphocytes were harvested from MLN and PP as
above with the recovery of 37.5 million MLN and 10.5
million PP lymphocytes from group I and 30.0 million
MLN and 12.3 million PP lymphocytes from group II,
separately fused with SP2 myeloma cells as above,
and plated in 120 master microtiter wells for each
of the four categories.
At 20 days post hybridization growth was determined
by observation with an inverted microscope and supernatants
collected and stored frozen at -70 C for 2 years before
assay by ELISA as above.
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RESULTS
Lymphocytes (xlO )
Wells cultured
Wells contaminated
Growing wells
4-6
Frequency (xlO )
Ig positive
IgA
IgG
IgM
Absorbance at 405 nm on ELISA for
Well IgA IgG IgM
Group I
MLN PP
37.5 10.5
120 120
0 0
3 22
12.5 0.5
0 7
0 2
0 2
0 3
IP1D6 .137 .355 1.047
IP1E7 .095 .603 .113
IP2B8 .110 .207 .731
IP2C7 .088 .615 .105
IP2C10 .357 .211 .104
IP2D8 .125 .238 .772
IP2E6 .338 .197 .101
IIP1B6 .339 .235 .108
IIP1C8 .109 .221 .652
IIP1E5 .303 .224 .108
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The large percentage of nongrowing wells on all
plates implies a high probability of monoclonality (90%)
in growing wells. Monoclonal origin of growing cultures
is assumed (see Appendix).
The optical density data obtained by ELISA of
the supernatants is unambiguous despite the relatively
poor specificity displayed by the alkaline phosphatase
conjugated goat anti mouse IgG.
Of note is the low hybridization frequency of
MLN lymphocytes with SP2, 1 per 5.6 million and the
lack of detectable immunoglobulin secretion of all
12 hybrids obtained.
PP lymphocytes fused with SP2 cells produced
hybridomas at a frequency of 1 per 470 thousand, 10
of the 35 (29%) were assayed as immunoglobulin secreting
with IgA, IgG, and IgM classes represented 4,2, and 4
times respectively.
The data indicate PP lymphocytes from an enterically
immunized and boostered animal are more likely to
hybridize than MLN lymphocytes with SP2 cells in this
protocol, X2(ldf)=85, P=.001f and that these PP hybrids
have a higher frequency of immunoglobulin production
2
than the MLN hybrids produced, Xc(ldf)=2.8, P=.10.
Antibody specificity was not investigated, nor
was an attempt made to assay IgA containing supernatants
for polymeric antibody.
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DISCUSSION
It was demonstrated that MLN and PP from enterically
immunized and boostered BALB/c mice can be harvested
under aseptic conditions with average recoveries of
7 and 2 million cells per animal respectively, quantities
useful for the study of cell surface and internal
immunoglobulin class frequencies.
Pooled tissue from many animals was required
to accumulate enough lymphocytes for fusion with SP2
myeloma cells to successfully yield immunoglobulin
secreting hybridomas.
MLN lymphocytes were shown to be poor fusion
partners with a hybridization frequency 1/10 that
of PP and splenic lymphocytes with SP2 cells. The
significant relative paucity of MLN hybrids might
stem from one or more causes including:
a) Differences in handling of the MLN and PP
SP2 fusomas . The MLN SP2 post fusion mix was plated
at 3 times the cell density of the PP SP2 mix.
Increasing cell density in the 1-10 million/ml
range typically does not effect or slightly increases
the frequency of recovery of splenic SP2 hybrids,
and unless MLN SP2 fusomas behave quite differently,
the cell density disparity of the cultures is unlikely
to be critical .
b) Differences in the B blast quantity or quality
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in the parent tissues.
Stahli et al demonstrated hybridization frequency
is directly proportional to the blast (identified by
cell volume) concentration of the splenic parent lymphocytes
(89).
If the concentration of B lymphoblasts present
in MLN is significantly different from that in PP
or if these MLN blasts are at a different stage of
differentiation less adept at forming hybridomas the
above discrepancy in frequencies is explicable.
Guy-Grand et al observed a PP:MLN ratio of B
cell blasts (identified by tritiated thymidine uptake
and the presence of surface immunoglobulin) in unimmunized
BALB/c mice of approximately 10:1 (53).
If it can be assumed that the definition of blast
by criteria based on cell volume identifies the same
set of cells as tritiated thymidine uptake and surface
immunoglobulin, then a simple difference in B blast
concentration in PP and MLN is a plausible explanation
for the poor showing of the MLN lymphocytes.
Perhaps the difference in blast concentration of
MLN and PP might be explained by Andre et al's hypothesis
concerning their observation that intragastrically
immunized BALB/c mice display a primary gut and splenic
(systemic) immune response, but that boostering fails
to elicit a secondary anamnestic reponse outside the
gut lamina propria (91,92). They conjecture primary
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gut immunoblasts travel from gut to MLN to thoracic
duct to bloodstream and finally settle in gland or
gut lamina propria, but that the gut memory lymphoblasts
induced by boostering do not travel. The differnce
in blast concentration of the MLN and PP might be
due to a lack of gut memory blasts in the MLN.
The lack of immunoglobulin production in all
12 MLN hybridomas might be explained by assuming:
a) A chance event. The difference in ability
of MLN and PP SP2 hybrids to secrete antibody was
2
statistically insignificant, P= . 1 by X
b) MLN and PP B blasts are at different stages
of differentiation with MLN blasts less inclined to
instruct MLN SP2 hybrids in the manufacture and secretion
of immunoglobulin.
Guy-Grand et al provide evidence for this maturation
argument with their observations on the increased
concentration of blasts with internal immunoglobulin
in MLN relative to PP, and the homing characteristics
of radiolabeled B blasts from those tissues injected
into mice (53). MLN blasts preferentially home to
MLN, PP and gut, while PP blasts prefer the spleen and
PP.
These observations and those of Andre et al above
hint that shortly after primary enteric immunization
spleen, MLN, and PP may all be good sources of immature
B blasts capable of fusing with SP2 cells to secrete
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immunoglobulin. The success of Colwell et al in generating
antigen specific polymeric IgA secreting hybridomas
by fusing splenic lymphocytes from intragastrically
immunized but unboostered germ free mice with non
secreting X63.Ag.8.653 myeloma cells is explicable
in light of the above (108).
c) Different ratios of helper and suppressor
T cells in MLN and PP in situ at the time of fusion
or perhaps even carried over in cell culture might
result in differences in the ability of MLN and PP SP2
hybridomas to manufacture and secrete immunoglobulin.
Richman et al have demonstrated enterically induced
systemic immune tolerance in mice is due to the post
intragastric immunization induction of suppressor
T lymphocytes in the gut which travel to spleen, peripheral
nodes, and perhaps MLN (70,71).
It is concievable that the failure of the MLN SP2
hybrids to secrete antibody may be another manifestation
of T cell enforced enterically induced systemic tolerance.
Failure to detect immunoglobulin in 25 of 35 (71%)
of PP SP2 hybridoma supernatants might be explained by:
a) Chance.
Goding points out early after fusion there is
a strong tendency for chromosome loss and overgrowth
with the metabolically advantaged non secreting mutants
of the original clone (20). Subcloning is generally
required to preserve secreting cultures.
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Collection of supernatants at 20 days post fusion
rather than immediately on noting macroscopic growth in
the interim was undoubtedly contributory.
b) The existance of PP B blast subsets at different
stages of maturation with some less inclined to instruct
PP SP2 hybrids in immunoglobulin manufacture and secretion
( see above) .
The observed ratio of the number of IgA: IgG: IgM
secreting hybrids is consistant with the 54:16:30
ratio of PP blasts displaying these surface antibodies
respectively as noted by Guy-Grand et al , X2(2df)=.185 (53).
Antigen specificities of the immunoglobulins were
not investigated. It was assumed intragastric immunization
and boostering with Freund's complete adjuvant would
result in generalized non specific GALT stimulation.
The ability to direct specificity of antibody
secreted by GALT derived hybridomas by enteric immunization
with antigen is an implicit assumption of this work.
Colwell et al and Dean et al produced antigen
specific secreting hybrids after intragastric immunization
of germ free mice and direct injection of antigen into
rat PP respectively (108,109).
IgA containing supernatants were not assayed
for polymeric product. It is conjectured IgA secreting
GALT derived hybrids will preferentially secrete polymeric
antibody.
Assay of these supernatants alongside a monomer
and polymer murine IgA supernatant from MOPC 315
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by SDS electrophoresis, electroblotting, and I
iodinated antibody probe autoradiography is currently
in progress (110).
Colwell et al and Dean et al produced IgA secreting
hybrids in mice and rats respectively, greater than
90% were found to secrete polymeric antibody (108,109).
This first step toward the design of a protocol
for generating GALT derived specific murine dimeric
IgA (+J) secreting hybridomas from enterically immunized
and boostered animals uncovered several obstacles.
MLN cells were found to be poor fusion partners
and the rare MLN SP2 hybrids did not secrete antibody.
The small number of PP lymphocytes recoverable
(2 million/BALB/c) require that tissue from 50 animals
be pooled to equal the number of cells available from
a single spleen.
Supplementing PP with jejunal and ileal lamina
propria lymphocytes (10-20 million/BALB/c) could reduce
requirements to 10 animals, but it remains to be seen
if these lymphocytes can be asept ically recovered
and if fusions with SP2 cells produce hybrids with
similar characteristics to PP SP2s.
Alternatively, harvesting MLN,PP, and splenic
lymphocytes one week after immunization without boostering
a la Colwell et al, taking advantage of the circulating
lymphoblasts of the primary gut immune response seems
particularly attractive since it may be possible to
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reduce tissue requirements to a single animal (108).
Once a suitable protocol has been established,
animals could be intragastrically immunized with sheep
red blood cells (SRBC) sensitized by incubation with an
unsubstituted LTA (from L. casei) to ensure anti backbone
production (93,94).
Supernatants could be tested for anti LTA activity
and IgA class by passive hemagglutination of sensitized
SRBC or ELISA (93,94,95,96,111). Anti backbone activity
could be verified by VDRL, and the polymeric nature
of the antibody established by gel electrophoresis,
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electroblotting, and I iodinated antibody probe
autoradiography (110). Most important, the functional
activity of the antibody could be demonstrated by its
ability to block streptococcal adherence to epithelia
in vitro (3,10,104).
The clinical potential of specific passive mucosal
immunity has barely been gauged largely because specific
agents were not available in quantity. That is about to
change.
Especially interesting is the recent unpublished
work of Colwell et al in producing murine polymeric
IgA anti S. mutans secreting hybrids (108).
A little 'mousewash' a day may keep the dentist away.
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APPENDIX
A NEW THEOREM -MURPHY'S LAW OF CLONING BY LIMITING DILUTION
Assuming progenitors independently Poisson distributed
with average number x interesting and y uninteresting per
culture, the probability of having placed i interesting
in culture with j uninteresting is:
P(i,j) = Pv(i) P (j) = e~X x1 e~y yjx y i! j!
The probability of an interesting culture being
monoclonal is:
PM = p(i,Q)
l-px()
Expressed in terms of the fraction of sterile
cultures s, and uninteresting (including sterile) u:
s ^ P = s In u ^ s In s , O^s^u^l
M u-1 s-1
Murphy's Law- The probability an interesting culture
is monoclonal is bounded below by the fraction of sterile
cultures and less than or equal that of a random growing
culture, (see Table 1)
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TABLE 1
PM = s In u
u-1
.5.
0.1 .2 .3 .4 .5 .6 .7 .8 .9 1.0
26%
20 40
17 34 52
15 31 46 61
14 28 42 55 69
13 26 38 51 64 77
12 24 36 48 59 71 83
11 22 33 45 56 67 78 89
11 21 32 42 53 63 74 84 95
10 20 30 40 50 60 70 80 90 100
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